Using Macitentan to inhibit these autologous tumoral EVs secretion, the binding to PD-1 and PD-L1 decreases and thus enhancing the CD8 + T cell-mediated tumour killing and anti-PD-L1 therapy [68]. Here, CD8A is linked to neoplasm.